Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.

Baxi SM, Greenblatt RM, Bacchetti P, Scherzer R, Minkoff H, Huang Y, Anastos K, Cohen M, Gange SJ, Young M, Shlipak MG, Gandhi M.

AIDS. 2014 Jan 2;28(1):59-66. doi: 10.1097/QAD.0000000000000033.

2.

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions.

Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. Epub 2007 Nov 19.

3.

Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.

Baxi SM, Scherzer R, Greenblatt RM, Minkoff H, Sharma A, Cohen M, Young MA, Abraham AG, Shlipak MG; Womenʼs Interagency HIV Study (WIHS).

AIDS. 2016 Feb 20;30(4):609-18. doi: 10.1097/QAD.0000000000000958.

4.

A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.

Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Quiros-Roldan E, Manili L, Guaraldi G, Lapadula G, Torti C.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):18-30. doi: 10.1097/QAI.0b013e31823a6124.

PMID:
21992924
5.

Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.

Wang X, Boffito M, Zhang J, Chung E, Zhu L, Wu Y, Patterson K, Kashuba A, Tebas P, Child M, Mahnke L, Bertz R.

AIDS Patient Care STDS. 2011 Sep;25(9):509-15. doi: 10.1089/apc.2011.0113. Epub 2011 Jul 19.

6.

Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.

Kamkuemah M, Kaplan R, Bekker LG, Little F, Myer L.

Trop Med Int Health. 2015 Apr;20(4):518-26. doi: 10.1111/tmi.12446. Epub 2014 Dec 12.

7.

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.

Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):59-66. doi: 10.1097/QAI.0b013e318289b4d2.

8.

Cystatin C and baseline renal function among HIV-infected persons in the SUN Study.

Overton ET, Patel P, Mondy K, Bush T, Conley L, Rhame F, Kojic EM, Hammer J, Henry K, Brooks JT; Sun Study Investigators.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):148-55. doi: 10.1089/AID.2011.0018. Epub 2011 May 25.

PMID:
21480819
9.

Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

Dumond JB, Adams JL, Prince HM, Kendrick RL, Wang R, Jennings SH, Malone S, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba AD.

HIV Med. 2013 Aug;14(7):401-9. doi: 10.1111/hiv.12017. Epub 2013 Feb 24.

10.

Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS; IMPAACT 1026s Study Team.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9. doi: 10.1097/QAI.0b013e31820fd093.

11.

Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S.

PLoS One. 2011;6(7):e22661. doi: 10.1371/journal.pone.0022661. Epub 2011 Jul 25.

12.

Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.

Cao Y, Han Y, Xie J, Cui Q, Zhang L, Li Y, Li Y, Song X, Zhu T, Li T.

BMC Infect Dis. 2013 Jul 1;13:301. doi: 10.1186/1471-2334-13-301.

13.

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A.

Antivir Ther. 2010;15(2):213-8. doi: 10.3851/IMP1517.

PMID:
20386076
14.

Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.

King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP; P1058 Protocol Team.

Antimicrob Agents Chemother. 2011 Sep;55(9):4290-4. doi: 10.1128/AAC.01334-10. Epub 2011 Jun 13.

15.

A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.

Scherzer R, Gandhi M, Estrella MM, Tien PC, Deeks SG, Grunfeld C, Peralta CA, Shlipak MG.

AIDS. 2014 Jun 1;28(9):1289-95. doi: 10.1097/QAD.0000000000000258.

16.

Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.

Lê MP, Landman R, Koulla-Shiro S, Charpentier C, Sow PS, Diallo MB, Ngom Gueye NF, Ngolle M, Le Moing V, Eymard-Duvernay S, Benalycherif A, Delaporte E, Girard PM, Peytavin G; DAYANA Study Group.

J Antimicrob Chemother. 2015 May;70(5):1517-21. doi: 10.1093/jac/dku532. Epub 2015 Jan 11.

PMID:
25583749
17.

Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.

Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, Pinto J, Santos B, Parsons T, Kearney B, Emel L, Herron C, Richardson P, Hudelson SE, Eshleman SH, George K, Fowler MG, Sato P, Mofenson L; HPTN 057 Protocol Team.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):33-41. doi: 10.1097/QAI.0b013e3182a921eb.

18.

Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.

Gupta SK, Anderson AM, Ebrahimi R, Fralich T, Graham H, Scharen-Guivel V, Flaherty JF, Fortin C, Kalayjian RC, Rachlis A, Wyatt CM.

PLoS One. 2014 Mar 20;9(3):e92717. doi: 10.1371/journal.pone.0092717. eCollection 2014.

19.

Prevalence and factors associated with renal dysfunction among HIV-infected patients.

Crum-Cianflone N, Ganesan A, Teneza-Mora N, Riddle M, Medina S, Barahona I, Brodine S.

AIDS Patient Care STDS. 2010 Jun;24(6):353-60. doi: 10.1089/apc.2009.0326.

20.

Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.

Calcagno A, Gonzalez de Requena D, Simiele M, D'Avolio A, Tettoni MC, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S.

Antimicrob Agents Chemother. 2013 Apr;57(4):1840-3. doi: 10.1128/AAC.02434-12. Epub 2013 Feb 4.

Supplemental Content

Support Center